These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 18384941)

  • 1. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
    Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z; Wenlv S
    Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
    Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
    Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
    Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
    Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
    Lexander H; Palmberg C; Hellman U; Auer G; Hellström M; Franzén B; Jörnvall H; Egevad L
    Proteomics; 2006 Aug; 6(15):4370-80. PubMed ID: 16888723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
    Qingyi Z; Lin Y; Junhong W; Jian S; Weizhou H; Long M; Zeyu S; Xiaojian G
    Cancer Invest; 2009 Aug; 27(7):794-801. PubMed ID: 19637042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
    Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E
    Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia.
    Xu K; Ling MT; Wang X; Wong YC
    Prostate Cancer Prostatic Dis; 2006; 9(3):293-7. PubMed ID: 16683014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expressions of endothelin-1 in benign prostatic hyperplasia and prostate cancer and their significance].
    Zhou WQ; Sun YH; Yin HL; Zhang ZY; Ge JP; Cheng W; Ma HQ; Wei W; Zhou SG; Ma HH; Gao JP
    Zhonghua Nan Ke Xue; 2007 Aug; 13(8):685-9. PubMed ID: 17918704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
    Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
    J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
    Chung JC; Oh MJ; Choi SH; Bae CD
    ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
    Lin JF; Xu J; Tian HY; Gao X; Chen QX; Gu Q; Xu GJ; Song JD; Zhao FK
    Int J Cancer; 2007 Dec; 121(12):2596-605. PubMed ID: 17722004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.